Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that it
will be presenting at the Sixth Annual Needham & Company Biotechnology
and Medical Technology Conference on June 13, 2007 at 9:30 a.m. EDT in
New York.
The presentation will be webcast live and can be accessed on the Sirtris
website, www.sirtrispharma.com,
in the investor relations section. A replay will be available
approximately twenty-four hours after the presentation and will be
available on the company’s website for two
weeks.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Sirtris Pharmaceuticals, its product candidates, and those
candidates' clinical potential. These forward-looking statements about
future expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the Company's potential inability to initiate and complete
preclinical studies and clinical trials for its product candidates, the
fact that none of the Company's product candidates has received
regulatory approvals, the potential inability of the Company to gain
market acceptance of the Company's product candidates, and those other
risks factors that can be found in the Company's filings with the
Securities and Exchange Commission. Actual results may differ materially
from those Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.